Medtronic begins the U.S. rollout of MiniMed 780G with Abbott's Instinct sensor, advancing diabetes care.
The critical details are that price action cleared a crucial hurdle in early 2025, formed a Golden Crossover, and confirmed a completed market reversal following the fiscal year 2026 (F2026) Q2 earnings release.
Shares of a major home improvement retailer lost ground after it missed quarterly profit forecasts, indicating homeowners are putting off remodeling projects amid economic uncertainty. Meanwhile, strong demand and procedure volumes helped drive a strong earnings report for a medical device company, and its shares advanced.
| - Industry | - Sector | Geoffrey Straub Martha CEO | NYSE Exchange | G5960L103 CUSIP |
| IE Country | 95,000 Employees | 26 Sep 2025 Last Dividend | 27 Sep 1999 Last Split | 13 Jan 1978 IPO Date |
Medtronic plc is a global leader in medical technology, specializing in the development, manufacture, and sale of device-based medical therapies. Serving healthcare systems, physicians, clinicians, and patients around the world, the company is dedicated to alleviating pain, restoring health, and extending life for millions of people. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic operates across various medical domains through its diverse portfolio which includes cardiovascular, medical surgical, neuroscience, and diabetes treatments and technologies.
Medtronic’s comprehensive range of products and services is categorized into four primary segments: